Laboratory Corp. of America Holdings (LH) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Laboratory Corp. of America Holdings (NYSE:LH) have been given an average recommendation of “Buy” by the eighteen brokerages that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $188.21.
Several research analysts have weighed in on the company. Goldman Sachs Group assumed coverage on Laboratory Corp. of America in a report on Monday, January 29th. They set a “buy” rating and a $205.00 target price on the stock. Mizuho set a $178.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a report on Wednesday, January 24th. Jefferies Group reiterated a “hold” rating and set a $176.00 target price on shares of Laboratory Corp. of America in a report on Tuesday, March 6th. ValuEngine upgraded Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Canaccord Genuity lifted their target price on Laboratory Corp. of America from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th.
In other news, Director Adam H. Schechter sold 1,263 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $169.29, for a total value of $213,813.27. Following the sale, the director now directly owns 7,297 shares in the company, valued at $1,235,309.13. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $167.36, for a total value of $1,405,824.00. Following the completion of the sale, the chief financial officer now owns 15,931 shares in the company, valued at $2,666,212.16. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.
Shares of Laboratory Corp. of America (NYSE LH) opened at $175.75 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.20 and a current ratio of 1.31. Laboratory Corp. of America has a 52 week low of $134.19 and a 52 week high of $181.71. The company has a market capitalization of $18,210.00, a price-to-earnings ratio of 24.38, a P/E/G ratio of 1.46 and a beta of 0.90.
Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.70 billion. During the same period in the previous year, the firm earned $2.15 earnings per share. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. analysts anticipate that Laboratory Corp. of America will post 11.54 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/03/11/laboratory-corp-of-america-holdings-lh-given-consensus-recommendation-of-buy-by-brokerages.html.
About Laboratory Corp. of America
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.